AMARIN CORP PLC\UK Increase (Decrease) in Deferred Revenue
AMARIN CORP PLC\UK (AMRN) reported Increase (Decrease) in Deferred Revenue of -$142.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-05-02
- AMARIN CORP PLC\UK increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$142.00K.
- AMARIN CORP PLC\UK increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$383.00K.
- AMARIN CORP PLC\UK increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $1.94M.
- AMARIN CORP PLC\UK increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$43.00K.
- AMARIN CORP PLC\UK increase (decrease) in deferred revenue for fiscal 2017 was $1.22M, a 38.12% increase from fiscal 2016.
- AMARIN CORP PLC\UK increase (decrease) in deferred revenue for fiscal 2016 was $884.00K, a 93.79% decline from fiscal 2015.
- AMARIN CORP PLC\UK increase (decrease) in deferred revenue for fiscal 2015 was $14.23M.
- AMARIN CORP PLC\UK increase (decrease) in deferred revenue for fiscal 2014 was -$1.70M, a 200.00% decline from fiscal 2013.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$142.00K 10-Q · filed 2018-05-02 | -$525.00K derived: sum of 2 quarters · filed 2018-05-02 | $1.42M derived: sum of 3 quarters · filed 2018-05-02 | $1.37M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-12-31 | -$383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $1.56M derived: sum of 2 quarters · filed 2018-02-27 | $1.51M derived: sum of 3 quarters · filed 2018-02-27 | $1.22M 10-K · filed 2018-02-27 |
| 2017-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $1.90M derived: sum of 2 quarters · filed 2017-11-01 | $1.60M 10-Q · filed 2017-11-01 | $1.31M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-06-30 | -$43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$336.00K 10-Q · filed 2017-08-02 | -$629.00K derived: sum of 3 quarters · filed 2018-05-02 | -$922.00K derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-03-31 | -$293.00K 10-Q · filed 2018-05-02 | -$586.00K derived: sum of 2 quarters · filed 2018-05-02 | -$879.00K derived: sum of 3 quarters · filed 2018-05-02 | -$1.17M derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | -$293.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$586.00K derived: sum of 2 quarters · filed 2018-02-27 | -$879.00K derived: sum of 3 quarters · filed 2018-02-27 | $884.00K 10-K · filed 2018-02-27 |
| 2016-09-30 | -$293.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$586.00K derived: sum of 2 quarters · filed 2017-11-01 | $1.18M 10-Q · filed 2017-11-01 | $947.00K derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | -$293.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $1.47M 10-Q · filed 2017-08-02 | $1.24M derived: sum of 3 quarters · filed 2018-02-27 | $1.08M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $1.76M 10-Q · filed 2017-05-03 | $1.53M derived: sum of 2 quarters · filed 2018-02-27 | $1.37M derived: sum of 3 quarters · filed 2018-02-27 | $1.37M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | -$230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$394.00K derived: sum of 2 quarters · filed 2018-02-27 | -$394.00K derived: sum of 3 quarters · filed 2018-02-27 | $14.23M 10-K · filed 2018-02-27 |
| 2015-09-30 | -$164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$164.00K derived: sum of 2 quarters · filed 2016-11-03 | $14.46M 10-Q · filed 2016-11-03 | $14.46M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $14.63M 10-Q · filed 2016-08-04 | $14.63M derived: sum of 3 quarters · filed 2017-03-01 | $14.63M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $14.63M 10-Q · filed 2016-05-05 | $14.63M derived: sum of 2 quarters · filed 2017-03-01 | $14.63M derived: sum of 3 quarters · filed 2017-03-01 | $14.63M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $0.00 derived: sum of 2 quarters · filed 2017-03-01 | $0.00 derived: sum of 3 quarters · filed 2017-03-01 | -$1.70M 10-K · filed 2017-03-01 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $0.00 derived: sum of 2 quarters · filed 2015-11-04 | -$1.70M 10-Q · filed 2015-11-04 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$1.70M 10-Q · filed 2015-08-06 | ||
| 2014-03-31 | -$1.70M 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | $1.70M 10-K · filed 2016-02-25 | |||
| 2013-03-31 | $2.87M 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |